Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma.

Blood Adv · 2022 · PMC9043939 · PMID 35143622

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a weak trendno p-value reported

Patients with a decrease in ctDNA of ≥50% after bortezomib did not have improved PFS compared with those with a <50% decrease (median, 3.5 years [95% CI, 1.9-2.9] vs 1.9 years [95% CI, 1.7-7.6]; P = .18), but these patients did demonstrate a weak trend toward improved PFS (supplemental Figure 10).

also in 1,404 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.